MONT ROBINS: Open Payments
NPI 1467440701 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$661 in 32 payments from 21 companies in 2025. Trend: 2023 $520 · 2024 $756 · 2025 $661
Food & beverage: $661
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $93 |
| Neurocrine BioSciences, Inc. | 4 | $77 |
| Lundbeck LLC | 2 | $52 |
| Amgen Inc. | 2 | $51 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $41 |
| GlaxoSmithKline, LLC. | 2 | $38 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Corcept Therapeutics | 1 | $24 |
| Boston Scientific Corporation | 1 | $24 |
| Organon LLC | 2 | $24 |
Products named: INGREZZA, VRAYLAR, REXULTI, EVENITY, CAPLYTA, TRELEGY ELLIPTA, Auvelity, Korlym.
Industry payments across UT — which companies pay providers there.
